Back to top
more

Zealand Pharma AS (ZLDPF)

(Delayed Data from OTC)

$50.14 USD

50.14
150

-0.06 (-0.12%)

Updated Aug 7, 2025 10:47 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Eli Lilly (LLY) Q1 Earnings Lag Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 450% and 7.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

by Zacks Equity Research

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of 9.68% and 75.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 0% and 0.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 64.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 10.20% and 30.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's What Could Help Zealand Pharma AS (ZLDPF) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?

by Zacks Equity Research

Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Computer Programs and Systems (CPSI) Q3 Earnings Beat Estimates

by Zacks Equity Research

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 12.50% and 2.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lumos (LUMO) delivered earnings and revenue surprises of -2.83% and 6.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of 146.77% and 64.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zealand Pharma A/S (ZLDPF) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Recent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's Why

by Zacks Equity Research

Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Zealand Pharma A/S (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Zealand Pharma A/S (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.